Related Experiment Video
Updated: Jul 10, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Advances in systemic therapies for advanced prostate cancer
Daniel S Childs1, Andrew W Hahn2, Praful Ravi3
1Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA Childs.Daniel@mayo.edu.
BMJ (Clinical Research Ed.)
|July 8, 2026
Summary
This review highlights advancements in prostate cancer management, focusing on earlier treatment with androgen receptor pathway inhibitors for high-risk disease and personalized therapies for metastatic castration-resistant prostate cancer (mCRPC). It also addresses managing long-term side effects in patients living longer.
Area of Science:
- Oncology
- Urology
- Medical Research
Background:
- Prostate cancer management has significantly advanced in the last 20 years.
- Innovations in metastatic disease detection, biomarker characterization, and treatment have improved patient outcomes.
Purpose of the Study:
- To review the latest progress in managing advanced prostate cancer, including high-risk biochemical recurrence, metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic castration-resistant prostate cancer (mCRPC).
- To discuss the evolving landscape of mCRPC, emphasizing personalized therapy selection and management of adverse events.
Main Methods:
- Literature review of landmark clinical trials and meta-analyses.
- Summary of recent advancements in diagnostic imaging and genomic biomarkers.
- Analysis of treatment strategies including chemotherapy, PARP inhibitors, and 177Lu-PSMA-617.
Main Results:
- Earlier use of androgen receptor pathway inhibitors improves outcomes in high-risk biochemical recurrence and mHSPC.
- mCRPC patient population is increasingly diverse, requiring tailored treatment approaches.
- Advanced imaging and genomic biomarkers enhance patient selection for personalized therapies.
- Chemotherapy, PARP inhibitors, and 177Lu-PSMA-617 play refined roles in mCRPC management.
Conclusions:
- Current prostate cancer management strategies emphasize earlier intervention and personalized treatment based on biomarkers.
- Longer patient survival necessitates a focus on managing treatment-related adverse events, including cardiac, hematologic, and bone health issues.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...